IMNM(Daily)Technical ChartImmunome Inc.
Formation: Double Bottom + Resisrance Line Breakout + RSI Divergence
Risk management: 1,5%
−5.38USD
−106.81 MUSD
14.02 MUSD
48.31 M
About Immunome, Inc.
Sector
Industry
CEO
Clay B. Siegall
Website
Headquarters
Bothell
Employees (FY)
55
Founded
2006
ISIN
US45257U1088
FIGI
BBG00BR93ZG8
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of IMNM is 16.07 USD — it has decreased by 6.46% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Immunome, Inc. stocks are traded under the ticker IMNM.
Immunome, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
IMNM stock is 11.60% volatile and has beta coefficient of 0.77. Check out the list of the most volatile stocks — is Immunome, Inc. there?
One year price forecast for Immunome, Inc. has a max estimate of 38.00 USD and a min estimate of 33.00 USD.
IMNM earnings for the last quarter are −0.36 USD per share, whereas the estimation was −0.17 USD resulting in a −111.76% surprise. The estimated earnings for the next quarter are −0.27 USD per share. See more details about Immunome, Inc. earnings.
Immunome, Inc. revenue for the last quarter amounts to 3.57 M USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 2.07 M USD.
Yes, you can track Immunome, Inc. financials in yearly and quarterly reports right on TradingView.
IMNM stock has fallen by 21.80% compared to the previous week, the month change is a 32.39% fall, over the last year Immunome, Inc. has showed a 196.49% increase.
IMNM net income for the last quarter is −92.63 M USD, while the quarter before that showed −4.35 M USD of net income which accounts for −2.03 K% change. Track more Immunome, Inc. financial stats to get the full picture.
Today Immunome, Inc. has the market capitalization of 1.03 B, it has decreased by 5.84% over the last week.
No, IMNM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMNM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Immunome, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 55.00 employees. See our rating of the largest employees — is Immunome, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Immunome, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Immunome, Inc. stock shows the buy signal. See more of Immunome, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Immunome, Inc. future price: according to them, IMNM price has a max estimate of 38.00 USD and a min estimate of 33.00 USD. Read a more detailed Immunome, Inc. forecast: see what analysts think of Immunome, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Immunome, Inc. EBITDA is −108.80 M USD, and current EBITDA margin is −776.16%. See more stats in Immunome, Inc. financial statements.